Sjögren’s syndrome causes clinically significant lung problems in roughly 9 to 20% of patients. The same immune system dysfunction that attacks moisture-producing glands can also target the airways, lung tissue, and the delicate structures where oxygen enters the bloodstream. Lung involvement ranges from a persistent dry cough to serious scarring that impairs breathing.
Common Symptoms of Lung Involvement
The earliest signs of lung problems in Sjögren’s are often vague enough to be mistaken for allergies, a lingering cold, or simple deconditioning. The most frequently reported symptom is shortness of breath, appearing in about 62% of patients with pulmonary involvement. A dry, persistent cough follows closely at 54%. Less common complaints include producing sputum (14%), chest pain (11%), and fever (7%).
What makes these symptoms tricky is that they develop gradually. You might notice you’re winded climbing stairs you used to handle easily, or you can’t shake a cough that’s been lingering for months. Because Sjögren’s itself causes dryness throughout the body, a dry cough can seem like just another part of the disease rather than a sign of something deeper in the lungs.
Interstitial Lung Disease: The Most Serious Concern
The biggest pulmonary threat in Sjögren’s is interstitial lung disease (ILD), a group of conditions where inflammation and scarring damage the tissue surrounding the air sacs in the lungs. This scarring makes the lung tissue stiffer, which makes it harder for oxygen to pass into the bloodstream.
Several patterns of ILD show up in Sjögren’s, and knowing which one you have matters for treatment and outlook. The most common pattern, accounting for about 45% of cases in studies examining tissue samples, involves widespread but relatively uniform inflammation and scarring. The scarring-dominant form of this pattern is far more common than the inflammation-dominant form, which has implications for how well the lungs can recover. A pattern involving more irregular, patchy scarring appears in roughly 16% of cases. About 15% of patients develop a pattern characterized by dense clusters of immune cells infiltrating the lung tissue, something particularly associated with Sjögren’s. Another pattern, where the body lays down temporary plugs of tissue in the airways and air sacs, accounts for about 7% of cases.
Around 40% of patients show more than one pattern on imaging, which is part of what makes diagnosis and management complex.
Airway Disease and Bronchiolitis
Sjögren’s doesn’t just affect the deep lung tissue. It also targets the airways themselves. The immune cells that characterize the disease can cluster around the small airways (bronchioles), causing inflammation known as bronchiolitis. This was present in 25% of cases in studies examining lung tissue. The hallmark of this process is the formation of small nodules of immune tissue along the airway walls, similar to the lymphoid tissue that builds up in the salivary glands.
Larger airways can also be affected. Chronic inflammation can lead to bronchiectasis, a condition where the airway walls become permanently widened and damaged, trapping mucus and increasing the risk of repeated infections. If you find yourself dealing with frequent respiratory infections on top of Sjögren’s, airway involvement is one possible explanation.
The Lymphoma Connection
One of the more concerning aspects of Sjögren’s is that the chronic immune activation it drives can, over time, push certain immune cells toward becoming cancerous. Between 5 and 10% of all Sjögren’s patients eventually develop a type of B-cell lymphoma. The most common form is MALT lymphoma, which arises from immune tissue that forms in organs where it doesn’t normally exist.
The lungs are one place this can happen. In one study of 13 patients with pulmonary MALT lymphoma, 54% met the diagnostic criteria for Sjögren’s. This type of lymphoma tends to grow slowly and often presents with the same symptoms as other Sjögren’s lung problems: a cough and gradually worsening shortness of breath. That overlap is one reason regular monitoring matters, since a slowly growing lymphoma can look like progressive lung inflammation on the surface.
How Lung Involvement Is Detected
High-resolution CT scanning is the gold standard for identifying lung disease in Sjögren’s. It can reveal patterns of scarring, airway thickening, and immune cell infiltration that a standard chest X-ray would miss. Pulmonary function tests (PFTs), which measure how much air you can move and how efficiently oxygen crosses into your blood, complement imaging by tracking how well your lungs are actually working over time.
For patients with known lung involvement who are stable or have minimal symptoms, guidelines from a consensus panel published in Chest recommend pulmonary function testing every 3 to 6 months initially to establish whether lung function is declining, stable, or (occasionally) improving. Once a trajectory is clear, most specialists repeat testing every 6 to 12 months. Basic breathing capacity is checked at each visit, with more comprehensive testing including gas transfer measurements done at longer intervals.
If you have Sjögren’s but no lung symptoms, there are no firm rules about routine screening. However, because symptoms can be subtle and develop slowly, bringing up any new or worsening cough or breathlessness with your rheumatologist is worth doing rather than waiting for a scheduled visit.
Treatment Approaches
Treatment depends on the type and severity of lung involvement. For patients whose imaging shows minimal changes and whose lung function tests are stable, close monitoring without medication may be appropriate. The goal is to avoid unnecessary immunosuppression while catching any decline early enough to intervene.
When lung function is declining or symptoms are significant, immunosuppressive medications are the primary approach. The most commonly used options work by dialing down the overactive immune response that’s driving inflammation and scarring in the lungs. For patients who don’t respond adequately to these first-line treatments, a biologic therapy that targets specific immune cells (B cells, the same ones responsible for the lymphoma risk) may be added. The practical experience for patients on these treatments involves regular blood work to monitor for side effects, periodic lung function testing to track response, and ongoing communication with both a rheumatologist and a pulmonologist.
Treatment can slow or stabilize lung function decline, but scarring that has already formed is generally permanent. That’s the core reason early detection and monitoring carry so much weight in Sjögren’s lung disease.
Long-Term Outlook
A meta-analysis examining survival in Sjögren’s patients with interstitial lung disease estimated the five-year survival rate at 82%. When adjusted for certain statistical factors, that figure rose to 88%. These numbers reflect the full range of severity, from mild, stable disease to progressive scarring.
The type of lung disease pattern matters for prognosis. Patterns dominated by inflammation rather than established scarring tend to respond better to treatment. The pattern with irregular, patchy scarring generally carries a less favorable outlook than the more uniform pattern that’s most common in Sjögren’s. Lymphoma-related lung disease, while serious, is often indolent and treatable when caught. The overall message is that lung involvement in Sjögren’s is manageable for most patients, but it requires consistent monitoring to catch changes before they become irreversible.